Q-omics provides the consensus-scored FAM110B profile across patient tissues and cancer cell-line models. FAM110B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, FAM110B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FAM110B RNA expression shows 20,838 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BLCA, KIRC, and BRCA as cancer lineages where FAM110B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM110B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM110B survival associations across molecular data types. FAM110B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM110B RNA expression–survival associations across cancer types. High FAM110B expression shows unfavorable associations in BLCA, UCEC, UVM and STAD, but favorable associations in LGG and PAAD. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for FAM110B RNA expression.
This table summarizes FAM110B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM110B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM110B shows lower tumor expression in KIRC, LUAD, BLCA, COAD and UCEC and higher tumor expression in BRCA. The KIRC box plot shows higher FAM110B RNA expression in normal versus tumor tissue (log2 FC = −1.231, t-test p < 0.001).
This table shows molecular features associated with FAM110B in patient tissues and cancer cell lines. In patient samples, FAM110B shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM110B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
